BACKGROUND: Patients with a failing Fontan continue to have decreased survival after heart transplant (HT), particularly those with preserved ventricular function (PVF) compared with impaired ventricular function (IVF). In this study we evaluated the effect of institutional changes on post-HT outcomes. METHODS: Data were retrospectively collected for all Fontan patients who underwent HT. Mode of failure was defined by the last echocardiogram before HT, with mild or no dysfunction considered PVF and moderate or severe considered IVF. Outcomes were compared between early era (EE, 1995 to 2008) and current era (CE, 2009 to 2014). Management changes in the CE included volume load reduction with aortopulmonary collateral (APC) embolization, advanced cardiothoracic imaging, higher goal donor/recipient weight ratio and aggressive monitoring for post-HT vasoplegia. RESULTS: A total of 47 patients were included: 27 in the EE (13 PVF, 14 IVF) and 20 in the CE (12 PVF, 8 IVF). Groups were similar pre-HT, except for more PLE in PVF patients. More patients underwent APC embolization in the CE (80% vs 28%, p < 0.01). There was no difference in donor/recipient weight ratio between eras. There was a trend toward higher primary graft failure for PVF in the EE (77% vs 36%, p = 0.05) but not the CE (42% vs 75%, p = 0.20). Overall, 1-year survival improved in the CE (90%) from the EE (63%) (p = 0.05), mainly due to increased survival for PVF (82 vs 38%, p = 0.04). CONCLUSIONS: Post-HT survival for failing Fontan patients has improved, particularly for PVF. In the CE, our Fontan patients had a 1-year post-HT survival similar to other indications.
BACKGROUND:Patients with a failing Fontan continue to have decreased survival after heart transplant (HT), particularly those with preserved ventricular function (PVF) compared with impaired ventricular function (IVF). In this study we evaluated the effect of institutional changes on post-HT outcomes. METHODS: Data were retrospectively collected for all Fontan patients who underwent HT. Mode of failure was defined by the last echocardiogram before HT, with mild or no dysfunction considered PVF and moderate or severe considered IVF. Outcomes were compared between early era (EE, 1995 to 2008) and current era (CE, 2009 to 2014). Management changes in the CE included volume load reduction with aortopulmonary collateral (APC) embolization, advanced cardiothoracic imaging, higher goal donor/recipient weight ratio and aggressive monitoring for post-HT vasoplegia. RESULTS: A total of 47 patients were included: 27 in the EE (13 PVF, 14 IVF) and 20 in the CE (12 PVF, 8 IVF). Groups were similar pre-HT, except for more PLE in PVFpatients. More patients underwent APC embolization in the CE (80% vs 28%, p < 0.01). There was no difference in donor/recipient weight ratio between eras. There was a trend toward higher primary graft failure for PVF in the EE (77% vs 36%, p = 0.05) but not the CE (42% vs 75%, p = 0.20). Overall, 1-year survival improved in the CE (90%) from the EE (63%) (p = 0.05), mainly due to increased survival for PVF (82 vs 38%, p = 0.04). CONCLUSIONS: Post-HT survival for failing Fontan patients has improved, particularly for PVF. In the CE, our Fontan patients had a 1-year post-HT survival similar to other indications.
Authors: Ryan R Davies; Robert A Sorabella; Jonathan Yang; Ralph S Mosca; Jonathan M Chen; Jan M Quaegebeur Journal: J Thorac Cardiovasc Surg Date: 2012-05 Impact factor: 5.209
Authors: Lisa Bergersen; Audrey Marshall; Kimberlee Gauvreau; Robert Beekman; Russel Hirsch; Susan Foerster; David Balzer; Julie Vincent; William Hellenbrand; Ralf Holzer; John Cheatham; John Moore; James Lock; Kathy Jenkins Journal: Catheter Cardiovasc Interv Date: 2010-02-15 Impact factor: 2.692
Authors: Guido Michielon; Joost P van Melle; Djoeke Wolff; Duccio Di Carlo; Jeffrey P Jacobs; Ilkka P Mattila; Hakan Berggren; Harald Lindberg; Massimo A Padalino; Bart Meyns; René Prêtre; Morten Helvind; Thierry Carrel; Tjark Ebels Journal: Eur J Cardiothorac Surg Date: 2014-07-17 Impact factor: 4.191
Authors: Anne I Dipchand; Leah B Edwards; Anna Y Kucheryavaya; Christian Benden; Fabienne Dobbels; Bronwyn J Levvey; Lars H Lund; Bruno Meiser; Roger D Yusen; Josef Stehlik Journal: J Heart Lung Transplant Date: 2014-08-14 Impact factor: 10.247
Authors: Rochus K Voeller; Deirdre J Epstein; Tracey J Guthrie; Sanjiv K Gandhi; Charles E Canter; Charles B Huddleston Journal: Ann Thorac Surg Date: 2012-05-26 Impact factor: 4.330
Authors: Paul Khairy; Susan M Fernandes; John E Mayer; John K Triedman; Edward P Walsh; James E Lock; Michael J Landzberg Journal: Circulation Date: 2007-12-10 Impact factor: 29.690
Authors: Eric R Griffiths; Aditya K Kaza; Moritz C Wyler von Ballmoos; Hugo Loyola; Anne Marie Valente; Elizabeth D Blume; Pedro del Nido Journal: Ann Thorac Surg Date: 2009-08 Impact factor: 4.330
Authors: Kevin K Whitehead; Matthew J Gillespie; Matthew A Harris; Mark A Fogel; Jonathan J Rome Journal: Circ Cardiovasc Imaging Date: 2009-07-08 Impact factor: 7.792
Authors: Barbara Cardoso; Andras Kelecsenyi; Jonathan Smith; Katrijn Jansen; Fabrizio De Rita; Mohamed Samy Nassar; Louise Coats Journal: JTCVS Open Date: 2021-08-13